Glucose tolerance in amyotrophic lateral sclerosis.

Area of Science:

• Endocrinology
• Neurology
• Metabolic Research

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Metabolic alterations, including glucose metabolism, are increasingly recognized in neurodegenerative conditions.
• The relationship between ALS and glucose metabolism requires further investigation.

Purpose of the Study:

• To investigate glucose tolerance and insulin dynamics in patients with amyotrophic lateral sclerosis (ALS).
• To compare glucose metabolism and insulin binding in ALS patients versus age- and obesity-matched controls.

Main Methods:

• Oral glucose tolerance test (OGTT) to measure blood glucose and plasma insulin levels.
• Measurement of 125I-insulin binding to circulating erythrocytes in a subgroup of patients.
• Comparison of metabolic parameters between 21 ALS patients and 10 control subjects.

Main Results:

• No significant differences in mean blood glucose levels during OGTT between ALS and control groups.
• Fasting plasma immunoreactive insulin was significantly higher in ALS patients.
• Plasma insulin increments and 125I-insulin binding showed no significant differences, suggesting no marked increase in insulin resistance.

Conclusions:

• This study did not find evidence of significant glucose intolerance or increased insulin resistance in ALS patients.
• Elevated fasting insulin in ALS warrants further research into underlying mechanisms.
• Glucose metabolism appears largely preserved in ALS, despite observed differences in fasting insulin levels.